

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock Code: 2509)*

**VOLUNTARY ANNOUNCEMENT**  
**QX030N/CLD-423 ACHIEVED FIRST SUBJECTS DOSING IN**  
**PHASE I CLINICAL TRIAL**  
**CALDERA THERAPEUTICS SECURED CUMULATIVE FUNDING OF**  
**US\$112.5 MILLION**

This announcement is made by Qyuns Therapeutics Co., Ltd. (the “**Company**”) on a voluntary basis to inform its shareholders and potential investors of an update on the business developments of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the first subjects have been dosed in a Phase I healthy volunteer trial of QX030N/CLD-423, a bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways.

As of the date of this announcement, the Company’s partner for QX030N/CLD-423, Caldera Therapeutics, Inc. (“**Caldera Therapeutics**”) has a total of US\$112.5 million capital raised. In April 2025, Caldera Therapeutics raised a US\$75 million Series A round from Atlas Venture, LAV and venBio, and most recently a US\$37.5 million Series A-1 round led by Omega Funds, with participation from new investors Wellington Management and Janus Henderson Investors.

**ABOUT QX030N/CLD-423**

Single targeted inflammatory bowel disease (“**IBD**”) therapies have hit an efficacy ceiling. Bispecifics are the next horizon of IBD treatment. QX030N/CLD-423 is a clinical stage bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways. Combining these two powerful autoimmune targets in a single molecule represents the next frontier in IBD treatment. QX030N/CLD-423 is rationally designed to achieve a best-in-disease profile with optimized efficacy, safety, pharmacokinetics and developability.

On April 23, 2025, the Company and Caldera Therapeutics entered into an out-license agreement (the “**License Agreement**”). The License Agreement has granted Caldera Therapeutics an exclusive right to develop and commercialize QX030N/CLD-423 globally. Please refer to the announcements issued by the Company on April 24, 2025 and December 9, 2025 for details.

## **ABOUT CALDERA THERAPEUTICS**

Caldera Therapeutics is a clinical stage company developing QX030N/CLD-423, a first-in-class bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways for the treatment of IBD and other immunologic and inflammatory diseases. Supported by leading biotech investors Atlas Venture, LAV, venBio, Omega Funds, Wellington Management and Janus Henderson Investors, Caldera Therapeutics has assembled a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building companies through to successful exits.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**  
*Chairman of the Board and Executive Director*

Hong Kong, January 14, 2026

*As of the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.*